Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture

Open access
Chakrabarty, Sanjiban, Quiros-Solano, William F., Kuijten, Maayke M.P., Haspels, Ben, Mallya, Sandeep, Lo, Calvin Shun Yu, Othman, Amr, Silvestri, Cinzia, van de Stolpe, Anja, Gaio, Nikolas, Odijk, Hanny, van de Ven, Marieke, de Ridder, Corrina M.A., van Weerden, Wytske M., Jonkers, Jos, Dekker, Ronald, Taneja, Nitika, Kanaar, Roland, van Gent, Dik C. · 2022 · Cancer Research

Published version of a preprint

Abstract

Optimal treatment of cancer requires diagnostic methods to facilitate therapy choice and prevent ineffective treatments. Direct assessment of therapy response in viable tumor specimens could fill this diagnostic gap. Therefore, we designed a microfluidic platform for assessment of patient treatment response using tumor tissue slices under precisely controlled growth conditions. The optimized Cancer-on-Chip (CoC) platform maintained viability and sustained proliferation of breast and prostate tumor slices for 7 days. No major changes in tissue morphology or gene expression patterns were observed within this time frame, suggesting that the CoC system provides a reliable and effective way to probe intrinsic chemotherapeutic sensitivity of tumors. The customized CoC platform accurately predicted cisplatin and apalutamide treatment response in breast and prostate tumor xenograft models, respectively. The culture period for breast cancer could be extended up to 14 days without major changes in tissue morphology and viability. These culture characteristics enable assessment of treatment outcomes and open possibilities for detailed mechanistic studies. SIGNIFICANCE: The Cancer-on-Chip platform with a 6-well plate design incorporating silicon-based microfluidics can enable optimal patient-specific treatment strategies through parallel culture of multiple tumor slices and diagnostic assays using primary tumor material.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-21-0799

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure. 1. Microfluidic CoC platform design and overview. A, Top view of the microfluidic chip illustrating its components: the PDMS film in which the microfluidics are embedded, the silicon frame, which includes the inlet and outlet to the channels in the film. Scale bar, 2.5 mm. B, Vertical cross-section of the microfluidic chip. The PDMS film with the microfluidic channel is supported by a silicon frame, which includes a well facing the PDMS layer. The microchannel and the well are separated by a microporous PDMS membrane (4-μm pore size). Scale bar, 100 μm. C, Representation of the CoC platform. The platform, which consists of a bottom and a top plate, houses the microfluidic chip and allows for its connection to external fluidics. The ring is used to seal the system, to maintain adequate pressure for the controlled flow within the fluidic channel, and to minimize leakage. Scale bar, 2 cm. D, Accessories of the CoC platform with two different top plate designs. We have used double flow for this study. E, Cross-section of CoC illustrating the diffusion and perfusion toward the tissue slice. First the tissue slice is added to the microfluidic chip, which is in turn sandwiched between the top and bottom plates and connected to the external pump. Breast PDX tissue slices were perfused with an inlet flowrate of 5 μL/minute through the top and bottom channels. F, CoC platform connected to Fluigent Microfluidic flow control system that was further connected to flowrate sensors (Fluigent FLOW UNIT-S) using Fluigent MAT for the entire culture period.
Figure. 1. Microfluidic CoC platform design and overview. A, Top view of the microfluidic chip illustrating its components: the PDMS film in which the microfluidics are embedded, the silicon frame, which includes the inlet and outlet to the channels in the film. Scale bar, 2.5 mm. B, Vertical cross-section of the microfluidic chip. The PDMS film with the microfluidic channel is supported by a silicon frame, which includes a well facing the PDMS layer. The microchannel and the well are separated by a microporous PDMS membrane (4-μm pore size). Scale bar, 100 μm. C, Representation of the CoC platform. The platform, which consists of a bottom and a top plate, houses the microfluidic chip and allows for its connection to external fluidics. The ring is used to seal the system, to maintain adequate pressure for the controlled flow within the fluidic channel, and to minimize leakage. Scale bar, 2 cm. D, Accessories of the CoC platform with two different top plate designs. We have used double flow for this study. E, Cross-section of CoC illustrating the diffusion and perfusion toward the tissue slice. First the tissue slice is added to the microfluidic chip, which is in turn sandwiched between the top and bottom plates and connected to the external pump. Breast PDX tissue slices were perfused with an inlet flowrate of 5 μL/minute through the top and bottom channels. F, CoC platform connected to Fluigent Microfluidic flow control system that was further connected to flowrate sensors (Fluigent FLOW UNIT-S) using Fluigent MAT for the entire culture period.CC BY-NC-ND · PubMed Central
Figure 2. Prediction of therapy response using cisplatin-sensitive and -resistant PDX in ex vivo and CoC platform. Three cisplatin-sensitive and three cisplatin-resistant breast PDX tumors were used in three independent experiments to study cisplatin response in ex vivo 6-well plate culture and CoC platform. Cisplatin-sensitive and -resistant PDX tumor tissue slices were exposed to 5 μg/mL cisplatin for 3 days and evaluated for cell proliferation (EdU incorporation, red nuclei) and apoptosis (TUNEL staining, green nuclei). DAPI stains all nuclei blue. A, Representative EdU and TUNEL staining of cisplatin-sensitive breast PDX. B, Quantification of the fraction of EdU-positive and TUNEL-positive cells showing breast PDXs (n = 3) were sensitive to cisplatin. C, Representative EdU and TUNEL staining of cisplatin-resistant breast PDX. D, Quantification of the fraction of EdU-positive and TUNEL-positive cells showing breast PDXs (n = 3) were insensitive to cisplatin therapy, thereby validating the application of CoC for therapy response for patient tumors. Ten fields of view were quantified from each breast PDX slice. Each point in the graph represents one breast PDX sample and SEM is indicated for all three tumors in the three independent experiments. Scale bar, 50 μm. E, Analysis of DNA damage response in cisplatin-sensitive and -resistant PDX treated with cisplatin. Cisplatin treatment induced more double-strand breaks in cisplatin-sensitive PDX than in cisplatin-resistant PDX. Scale bar 50 μmol/L. F, Scatter plot showing 53BP1 foci count per cell in cisplatin-sensitive and -resistant PDX. Averages and SEM are indicated. Cis, cisplatin; cis res, cisplatin-resistant; cis sen, cisplatin-sensitive; H&E, hematoxylin and eosin. NS, not significant; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Figure 2. Prediction of therapy response using cisplatin-sensitive and -resistant PDX in ex vivo and CoC platform. Three cisplatin-sensitive and three cisplatin-resistant breast PDX tumors were used in three independent experiments to study cisplatin response in ex vivo 6-well plate culture and CoC platform. Cisplatin-sensitive and -resistant PDX tumor tissue slices were exposed to 5 μg/mL cisplatin for 3 days and evaluated for cell proliferation (EdU incorporation, red nuclei) and apoptosis (TUNEL staining, green nuclei). DAPI stains all nuclei blue. A, Representative EdU and TUNEL staining of cisplatin-sensitive breast PDX. B, Quantification of the fraction of EdU-positive and TUNEL-positive cells showing breast PDXs (n = 3) were sensitive to cisplatin. C, Representative EdU and TUNEL staining of cisplatin-resistant breast PDX. D, Quantification of the fraction of EdU-positive and TUNEL-positive cells showing breast PDXs (n = 3) were insensitive to cisplatin therapy, thereby validating the application of CoC for therapy response for patient tumors. Ten fields of view were quantified from each breast PDX slice. Each point in the graph represents one breast PDX sample and SEM is indicated for all three tumors in the three independent experiments. Scale bar, 50 μm. E, Analysis of DNA damage response in cisplatin-sensitive and -resistant PDX treated with cisplatin. Cisplatin treatment induced more double-strand breaks in cisplatin-sensitive PDX than in cisplatin-resistant PDX. Scale bar 50 μmol/L. F, Scatter plot showing 53BP1 foci count per cell in cisplatin-sensitive and -resistant PDX. Averages and SEM are indicated. Cis, cisplatin; cis res, cisplatin-resistant; cis sen, cisplatin-sensitive; H&E, hematoxylin and eosin. NS, not significant; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.CC BY-NC-ND · PubMed Central
Figure 3. Response to apalutamide treatment in CoC platform. A, PC82 tumor tissue slices cultured with apalutamide for 7 days and evaluated for AR expression, cell proliferation (EdU incorporation, red nuclei), and apoptosis (TUNEL staining, green nuclei). AR staining for PC82 tissue slice sections at day 0, day 7 ex vivo culture condition, and CoC platform with and without apalutamide treatment. DAPI stains all nuclei blue. H&E, hematoxylin and eosin. Scale bar, 50 μm. B, Quantification of the AR expression in prostate PDX slices cultured in ex vivo and CoC platform. C and D, Apalutamide treatment showed a significant increase in TUNEL-positive cells and significant decrease in EdU-positive cells when compared with untreated tumor slices in our CoC platform. Ten fields of view were quantified per prostate PDX slice. Each point in the graph represents one image field and SEM is indicated for 10 fields. D7, day 7; D0, day 0. ***, P < 0.001; ****, P < 0.0001.
Figure 3. Response to apalutamide treatment in CoC platform. A, PC82 tumor tissue slices cultured with apalutamide for 7 days and evaluated for AR expression, cell proliferation (EdU incorporation, red nuclei), and apoptosis (TUNEL staining, green nuclei). AR staining for PC82 tissue slice sections at day 0, day 7 ex vivo culture condition, and CoC platform with and without apalutamide treatment. DAPI stains all nuclei blue. H&E, hematoxylin and eosin. Scale bar, 50 μm. B, Quantification of the AR expression in prostate PDX slices cultured in ex vivo and CoC platform. C and D, Apalutamide treatment showed a significant increase in TUNEL-positive cells and significant decrease in EdU-positive cells when compared with untreated tumor slices in our CoC platform. Ten fields of view were quantified per prostate PDX slice. Each point in the graph represents one image field and SEM is indicated for 10 fields. D7, day 7; D0, day 0. ***, P < 0.001; ****, P < 0.0001.CC BY-NC-ND · PubMed Central
Figure 4. Breast PDX tumor tissue slices cultured in ex vivo condition and in CoC platform for up to 14 days. A, We used five independent breast PDX tumors in five independent experiments to establish optimized culture condition for tumor slices in our CoC platform. From each breast PDX tumor, tissue slices were cultured in ex vivo 6-well plate and CoC device for up to 14 days and evaluated for tissue morphology [hematoxylin and eosin (H&E) staining], DAPI (blue nuclei), proliferation (EdU incorporation, red nuclei), Ki67 (brown nuclei), and apoptosis (TUNEL staining, green nuclei). Scale bar, 50 μm. B and C, Quantification of the fraction of EdU-positive and TUNEL-positive cells for 5 breast PDX tissue slices (derived from individual PDX tumors) cultured for up to day 7 (B) and day 14 (C). For each breast PDX tumor and each condition, tissue slices were imaged, and ten random fields of view were quantified from each breast PDX slice. Each data point in the graph represents one image field. Error bar represents the SEM for the five independent tumors performed in five independent experiments. D, Representative image showing breast PDX tumors (n = 3) labeled with geminin (red nuclei) and DAPI (blue nuclei). Scale bar, 50 μm. E, QIBC analysis of three independent breast PDX tumors with more than 3,000 cells analyzed for each are shown in each condition. F, Quantification of geminin-positive cells showed CoC at day 7 had similar cell proliferation profile as in day 0 than ex vivo condition. Error bar, SEM. NS, not significant; D0, day 0; D7, day 7, D14, day 14. NS, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Figure 4. Breast PDX tumor tissue slices cultured in ex vivo condition and in CoC platform for up to 14 days. A, We used five independent breast PDX tumors in five independent experiments to establish optimized culture condition for tumor slices in our CoC platform. From each breast PDX tumor, tissue slices were cultured in ex vivo 6-well plate and CoC device for up to 14 days and evaluated for tissue morphology [hematoxylin and eosin (H&E) staining], DAPI (blue nuclei), proliferation (EdU incorporation, red nuclei), Ki67 (brown nuclei), and apoptosis (TUNEL staining, green nuclei). Scale bar, 50 μm. B and C, Quantification of the fraction of EdU-positive and TUNEL-positive cells for 5 breast PDX tissue slices (derived from individual PDX tumors) cultured for up to day 7 (B) and day 14 (C). For each breast PDX tumor and each condition, tissue slices were imaged, and ten random fields of view were quantified from each breast PDX slice. Each data point in the graph represents one image field. Error bar represents the SEM for the five independent tumors performed in five independent experiments. D, Representative image showing breast PDX tumors (n = 3) labeled with geminin (red nuclei) and DAPI (blue nuclei). Scale bar, 50 μm. E, QIBC analysis of three independent breast PDX tumors with more than 3,000 cells analyzed for each are shown in each condition. F, Quantification of geminin-positive cells showed CoC at day 7 had similar cell proliferation profile as in day 0 than ex vivo condition. Error bar, SEM. NS, not significant; D0, day 0; D7, day 7, D14, day 14. NS, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.CC BY-NC-ND · PubMed Central
Figure 5. Gene expression analysis of breast PDX tumor cultured in ex vivo and CoC platform. Three independent breast PDX tumors (P1, P2, and P3) were used for analysis of pathway activity using OncoSignal and RNA-seq for whole mRNA expression analysis. A, Seven major pathways were analyzed (ER, AR, PI3K, and MAPK growth factor pathways, HH, Notch, and TGFβ cell signaling pathways) using OncoSignal. Pathway activity scores are presented on a normalized scale of 0 to 100. Error bars, SEM. Mann–Whitney test of seven pathway activity across PDX tumor slices (day 0, day 7, day 14) in ex vivo and CoC condition did not show any statistically significant change. B, Venn diagram showing differentially expressed human (ex vivo-D7, CoC-D7, and CoC-D14) genes (logFC > 1.5 or logFC ≤ 1.5, FDR < 0.1) in PDX tumors at day 7 and day 14 in ex vivo and CoC platform when compared with day 0 PDX tumors. C, Heatmap diagram showing IFN signaling pathway gene expression at different days in ex vivo and in CoC platform culture condition. D, Network diagram showing top ranked networks significantly enriched in immune signaling and tumor microenvironment (P < 0.05) exclusively in day 7 ex vivo culture condition. Orange, predicted activation of the pathways (Z score > 2); blue, predicted inhibition (Z score ≤2). E, Representative image showing 53BP1 staining in breast PDX tumors cultured at day 0, day 7 ex vivo and CoC condition. DAPI staining is shown as blue nuclei. Scale bar, 50 μm. F, Bar chart showing the percentage of cells with 53BP1 foci. Error bar, SEM for the three independent PDX tumor samples. D0, day 0; D7, day 7, D14, day 14. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.
Figure 5. Gene expression analysis of breast PDX tumor cultured in ex vivo and CoC platform. Three independent breast PDX tumors (P1, P2, and P3) were used for analysis of pathway activity using OncoSignal and RNA-seq for whole mRNA expression analysis. A, Seven major pathways were analyzed (ER, AR, PI3K, and MAPK growth factor pathways, HH, Notch, and TGFβ cell signaling pathways) using OncoSignal. Pathway activity scores are presented on a normalized scale of 0 to 100. Error bars, SEM. Mann–Whitney test of seven pathway activity across PDX tumor slices (day 0, day 7, day 14) in ex vivo and CoC condition did not show any statistically significant change. B, Venn diagram showing differentially expressed human (ex vivo-D7, CoC-D7, and CoC-D14) genes (logFC > 1.5 or logFC ≤ 1.5, FDR < 0.1) in PDX tumors at day 7 and day 14 in ex vivo and CoC platform when compared with day 0 PDX tumors. C, Heatmap diagram showing IFN signaling pathway gene expression at different days in ex vivo and in CoC platform culture condition. D, Network diagram showing top ranked networks significantly enriched in immune signaling and tumor microenvironment (P < 0.05) exclusively in day 7 ex vivo culture condition. Orange, predicted activation of the pathways (Z score > 2); blue, predicted inhibition (Z score ≤2). E, Representative image showing 53BP1 staining in breast PDX tumors cultured at day 0, day 7 ex vivo and CoC condition. DAPI staining is shown as blue nuclei. Scale bar, 50 μm. F, Bar chart showing the percentage of cells with 53BP1 foci. Error bar, SEM for the three independent PDX tumor samples. D0, day 0; D7, day 7, D14, day 14. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 63

Metadata

Authors
Chakrabarty, S., Quiros-Solano, W. F., Kuijten, M. M. P., Haspels, B., Mallya, S., Lo, C. S. Y., Othman, A., Silvestri, C., van de Stolpe, A., Gaio, N., Odijk, H., van de Ven, M., de Ridder, C. M. A., van Weerden, W. M., Jonkers, J., Dekker, R., Taneja, N., Kanaar, R., & van Gent, D. C.
Affiliations
  • Manipal Academy of Higher Education (IN)
  • 3Department of Microelectronics, Electronic Components, Technology and Materials, Delft University of Technology, Delft, the Netherlands.
  • Erasmus MC (NL)
  • 4BIOND Solutions B.V., Delft, the Netherlands.
  • 7Philips Research, Eindhoven, the Netherlands.
  • 8Preclinical Intervention Unit, Mouse Clinic for Cancer and Ageing, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • 9Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • The Netherlands Cancer Institute (NL)
  • Delft University of Technology (NL)
  • 1Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Venue
Cancer Research
Published
2021-12-06
Volume
82
Issue
3
Pages
510-520
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W4200376156
Cited by
61
References
52
Citations by year
2026: 15 · 2025: 14 · 2024: 12 · 2023: 13 · 2022: 7
FWCI
2.43
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • Research Repository (Delft University of Technology) (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • KWF Kankerbestrijding (KWF11011)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (737.016.011)
  • Electronic Components and Systems for European Leadership (H2020-ECSEL-2019-IA-876190)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
drug response prediction, microfluidic platform, breast cancer, prostate cancer, cisplatin, apalutamide, chemosensitivity, xenograft models, personalized treatment, silicon microfluidics, primary tumor tissue
MeSH terms
Humans, Organ Culture Techniques, Gene Expression, Microfluidics, Biomarkers, Pharmacological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture. https://app.cochat.ai/papers/10.1158/0008-5472.can-21-0799
The paper
Chakrabarty, S., Quiros-Solano, W. F., Kuijten, M. M. P., Haspels, B., Mallya, S., Lo, C. S. Y., Othman, A., Silvestri, C., van de Stolpe, A., Gaio, N., Odijk, H., van de Ven, M., de Ridder, C. M. A., van Weerden, W. M., Jonkers, J., Dekker, R., Taneja, N., Kanaar, R., & van Gent, D. C. (2022). A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture. Cancer Research. https://doi.org/10.1158/0008-5472.can-21-0799

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.